Quantifying the expression of the transcription factor Nrf2 in our cohort, we observed significantly increased mRNA levels in LRRK2+/PD+ individuals (median: 1.18, IQR: 0.92–1.38) compared to controls (median: 0.79, IQR: 0.65–1.03; Kruskal–Wallis followed by Dunn's tests: p = 0.033). This evidence concerns the gene NFE2L2 and Parkinson disease.